An observational study in Colorectal Cancer, Ovarian Cancer and Peritoneal Disease, sponsored by Tata Memorial Centre. Recruiting at 1 site in India. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-11-21.
Sponsored by Tata Memorial Centre · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Colorectal Neoplasms with a site in India — 8 open to participants now, 13 under way, 7 of them phase 3. Colorectal Neoplasms · India.
Among the 33 studies in Colorectal Neoplasms with a site in India, this one is the only one that started in 2016, is one of 5 observational ones, reaches primary completion later than 5 of the 12 other live ones, and was the 19th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →8 of the 33 studies in Colorectal Neoplasms with a site in India are open now. Recruiting first, the newest first:
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–85
Bristol-Myers Squibb · Sites in India, United States, Argentina and 22 more countries
Ages 18+
Pfizer · Sites in India, United States, Argentina and 17 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in India, United States, Australia and 23 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in India, United States, Belgium and 19 more countries
Ages 18+
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 14 · Phase 4 2
First in 2006; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 250 across 1,444 observational studies indexed under Colorectal Neoplasms.
Median enrollment 480 across the 28 interventional studies, 188 across the 5 observational. Of the 18 that completed or were terminated, 11 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 33 have an industry lead sponsor. The 10 most frequent:
Tata Memorial Centre is the lead sponsor of 64 studies on the registry; 42 are open to participants now.
Tata Memorial Centre has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Colorectal Neoplasms with a site in India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02754115Tata Memorial CentreAn Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy | 2026-12 |
| NCT04482309AstraZenecaA Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | 2027-03-23 |
Add all 2 to your calendar (.ics) → With an account.
Among the 33 studies in Colorectal Neoplasms with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Peritoneal carcinomatosis is a common event in the natural history of colorectal and other digestive tract cancers. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) provides a promising therapeutic option for highly selected patients with peritoneal carcinomatosis arising from different malignancies such as colorectal cancer, gastric cancer, ovarian cancer, or peritoneal mesothelioma with improvement of both patient survival and quality of life. CRS, i.e., removal of all visible metastatic abdominal and pelvic disease with peritonectomy along with HIPEC (for 90 min at a temperature of 42º C) and/or early postoperative intraperitoneal chemotherapy (EPIC) in order to eradicate all microscopic metastasis.
CRS with HIPEC is a long and complex procedure with significant blood and fluid loss during debulking, hemodynamic, hematological, and metabolic alterations before and during the HIPEC phase, and even in the early postoperative period, with resultant significant morbidity and mortality. Despite that most of the reported patients are in American Society of Anesthesiologist class I and II, without significant comorbidities or systemic disorder; the morbidity and mortality ranges from 12 to 65% in these procedures, so a well coordinated team of anesthesiologist, surgeons and intensivist and other ancillary services can result in good outcome. This study will see the challenges faced by the team regarding the pathophysiological alterations during the CRS with HIPEC in the perioperative period.
American Society of Anesthesiologist class I, II and III patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Perioperative data of all the patients posted for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be collected prospectively
Changes in invasive blood pressure in perioperative period
Invasive blood pressure will be measured in radial artery in perioperative period and changes from baseline will be recorded in a graphical manner
Time frame: From start of surgery upto 48 hours after surgery
Changes in body temperature in perioperative period
Body temperature will be measured in degree centigrade by nasopharyngeal temperature probe in perioperative period and changes from baseline will be recorded in a graphical manner
Time frame: From start of surgery upto 48 hours after surgery
Changes in cardiac output in perioperative period
Cardiac output will be measured in perioperative period and changes from baseline will be recorded in a graphical manner
Time frame: From start of surgery upto 48 hours after surgery
Changes in arterial blood gas in perioperative period
Arterial blood gases will be measured in perioperative period and changes from baseline will be recorded in a graphical manner
Time frame: From start of surgery upto 48 hours after surgery
Length of stay in intensive care unit
Length of stay will be measured in days from admission to discharge in intensive care unit
Time frame: Upto 30 days after surgery
Mortality
30 days mortality will be noted if death occurred within this period
Time frame: Upto 30 days after surgery
Plan to share: Yes
No publications or documents are linked to this record.
Started Apr 2016 (actual). Primary completion is estimated for Dec 2026, 128 months after the start.
Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 128 months is above that.
Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tata Memorial Centre